2. Outcome measures reported in studies comparing alternative LE versus pure soy oil based LE.
Study | LE | N |
Death before D/C |
Growth rate (g/kg/d) |
Days to regain bw |
BPD |
Vent durn (d) |
O2 (d) |
Any sepsis |
NEC | IVH | HB |
PTx (d) |
HG | HTG | PNALD | PDA | ROP |
Beken 2014 | MOFS | 80 | Y | ‐ | ‐ | Y | Y | Y | Y | Y | Y | ‐ | ‐ | Y | ‐ | Y | ‐ | Y |
D'ascenzo 2014 | MOFS | 80 | Y | Y | Y | Y | ‐ | ‐ | Y | Y | Y | ‐ | ‐ | ‐ | NU | Y | Y | Y |
Demirel 2011 | OS | 40 | ‐ | NU | ‐ | NU | ‐ | ‐ | Y | NU | Y | ‐ | ‐ | ‐ | Y | ‐ | ‐ | NU |
Deshpande 2009 | OS | 50 | ‐ | NU | ‐ | ‐ | ‐ | ‐ | NU | ‐ | NU | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
Gawecka 2008 | OS | 44 | ‐ | ‐ | ‐ | Y | Y | Y | Y | Y | NU | ‐ | Y | ‐ | ‐ | Y | ‐ | NU |
Gobel 2003 | OS | 45 | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | Y | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ |
Koksal 2011 | OS | 64 | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | ‐ | Y | Y | Y | ‐ | NU |
Lehner 2006 | MS | 15 | ‐ | NU | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | Y | ‐ | ‐ | ‐ |
Rayyan 2012 | MOFS | 53 | Y | Y | ‐ | NU | ‐ | NU* | ‐ | ‐ | NU | ‐ | NU | NU | NU | ‐ | ‐ | |
Rubin 1994 | MS | 59 | ‐ | NU | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | ‐ | NU | ‐ | ‐ | ‐ | ‐ |
Savini 2013 | OS/MS/ MFS/MOFS |
150 | Y | Y | Y | Y | ‐ | ‐ | Y | Y | ‐ | ‐ | ‐ | ‐ | ‐ | Y | Y | ‐ |
Skouroliakou 2010 | MOFS | 38 | ‐ | NU | ‐ | ‐ | Y | ‐ | Y | ‐ | ‐ | ‐ | Y | Y | ‐ | ‐ | ‐ | ‐ |
Tomsits 2010 | MOFS | 60 | ‐ | Y | ‐ | ‐ | Y* | Y* | NU* | ‐ | ‐ | ‐ | ‐ | NU | NU | ‐ | ‐ | ‐ |
Vlaardingerbroek 2014 | MOFS | 98 | Y | Y | Y | Y | Y | ‐ | Y | Y | Y | ‐ | ‐ | ‐ | Y | Y | Y | Y |
Wang 2015 | OS | 103 | Y | NU | Y | Y | Y | ‐ | Y | NU | ‐ | ‐ | ‐ | ‐ | ‐ | Y | ‐ | ‐ |
LE: lipid emulsion N: total enrolled infants in the study FU: follow‐up D/C: discharge bw: birth weight BPD: bronchopulmonary dysplasia Vent durn: ventilation duration d: days 02: duration of supplemental oxygen NEC: necrotising enterocolitis > stage 2 IVH: intraventricular haemorrhage stage III/IV HB: hyperbilirubinaemia PTx: phototherapy HG: hyperglycaemia HTG: hypertriglyceridaemia PNALD: parenteral nutrition associated liver disease PDA: any patent ductus arteriosus ROP: retinopathy of prematurity MOFS: medium chain triglycerides‐olive‐fish‐soy OS: olive‐soy MS: medium chain triglycerides‐soy MFS: medium chain triglycerides‐fish‐soy Y: data reported and used in the meta‐analysis ‐: outcome not reported NU: data provided in a format not usable in meta‐analysis or reported as “no difference between groups” * composite outcomes reported Not all outcomes could be presented due to space constraints.